Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease

被引:61
作者
Bialecka, Monika [1 ]
Kurzawski, Mateusz [1 ]
Roszmann, Anna [5 ,6 ]
Robowski, Piotr [5 ,6 ]
Sitek, Emilia J. [5 ,6 ]
Honczarenko, Krystyna [2 ]
Gorzkowska, Agnieszka [7 ]
Budrewicz, Slawomir [8 ]
Mak, Monika [3 ]
Jarosz, Monika [4 ]
Golab-Janowska, Monika [2 ]
Koziorowska-Gawron, Ewa [8 ]
Drozdzik, Marek [1 ]
Slawek, Jaroslaw [5 ,6 ]
机构
[1] Pomeranian Med Univ, Dept Expt & Clin Pharmacol, PL-70111 Szczecin, Poland
[2] Pomeranian Med Univ, Clin Neurol, PL-70111 Szczecin, Poland
[3] Pomeranian Med Univ, Clin Psychiat, PL-70111 Szczecin, Poland
[4] Marie Curie Reg Hosp, Dept Neurol, Szczecin, Poland
[5] Med Univ Gdansk, Dept Neurol Psychiat Nursing, Gdansk, Poland
[6] St Adalbert Hosp, Dept Neurol, Gdansk, Poland
[7] Silesian Med Univ Katowice, Dept Neurol, Katowice, Poland
[8] Med Univ Wroclaw, Dept Neurol, Wroclaw, Poland
关键词
dementia; genetic polymorphism; homocysteine; levodopa; Parkinson's disease; CATECHOL-O-METHYLTRANSFERASE; MINI-MENTAL-STATE; PLASMA HOMOCYSTEINE; L-DOPA; CLINICAL-IMPLICATIONS; SERUM HOMOCYSTEINE; LEVODOPA TREATMENT; ALZHEIMER-DISEASE; TREATED PATIENTS; C677T GENOTYPE;
D O I
10.1097/FPC.0b013e32835693f7
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction Elevated plasma homocysteine (Hcy) concentration is an independent risk factor for cardiovascular disease, and its involvement in endothelial cell dysfunction is well established. However, the role of Hcy and folate in the pathogenesis of Parkinson's disease (PD) remains controversial. Objectives The study was aimed at evaluating the relationships between Hcy, vitamin B12, and folic acid levels in the blood and cognitive status in PD patients with the genetic polymorphisms of MTHFR (rs1801133: C>T-677C>T, rs1801131: A>C-1298A>C), COMT (rs4680: A>G-Val158Met, rs6269: A>G, rs4633: C>T, rs4818: C>G), or SLC19A1 (rs1051266: G>A-80G>A). Methods A total of 502 participants (248 with PD and 254 age-matched and sex-matched controls) were included in the study. The Unified Parkinson's Disease Rating Scale score, Hoehn-Yahr staging, and the Schwab-England scale were used to assess motor abilities and activity during daily life. Complex psychological examination with a battery of tests was used to classify patients into groups with (PDD) and without (nPDD) dementia. Blood samples were examined for Hcy, vitamin B12, and folic acid levels, as well as polymorphisms in genes related to Hcy metabolism, such as COMT, MTHFR, and SLC19A1(RFC-1). Results The frequency of homozygous COMT rs4680G and rs4633C allele carriers was significantly decreased in PD patients in comparison with the controls (P = 0.015; odds ratio = 0.60; 95% confidence interval 0.41-0.90 and P= 0.020; odds ratio = 0.619; 95% confidence interval 0.42-0.92, respectively). No significant differences in the distribution of MTHFR 677C>T, 1298A>C, and SLC19A1 80G>A alleles and genotypes between PD patients and the controls were found. Hcy levels were significantly increased in PD patients (18 +/- 7.8 mu mol/l) as compared with the controls (14.0 +/- 9.6 mu mol/l, P= 10(-8)) and were significantly associated with the MTHFR 677C>T polymorphism both in PD patients and controls, in which T allele carriers were characterized by markedly elevated Hcy plasma concentrations. No association was observed between Hcy plasma level and COMT and SLC19A polymorphisms. The results of multivariate logistic regression analysis revealed age (P= 0.0003) and Hcy plasma levels (P = 0.07) as independent risk factors predisposing individuals to PD dementia. The studied polymorphisms were not associated with cognitive status in PD patients. Conclusion The genetic factors studied were not associated with cognitive status in PD patients. Only age and Hcy plasma levels were found to be independent risk factors predisposing individuals to PD dementia. However, COMT: rs4680: A>G and rs4633: C>T polymorphisms were found to significantly affect PD risk, and the MTHFR 677C>T polymorphism helped determine plasma Hcy concentrations. Pharmacogenetics and Genomics 22: 716-724 (C) 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:716 / 724
页数:9
相关论文
共 61 条
[51]   MUTATED METHYLENETETRAHYDROFOLATE REDUCTASE AS A RISK FACTOR FOR SPINA-BIFIDA [J].
VANDERPUT, NMJ ;
STEEGERSTHEUNISSEN, RPM ;
FROSST, P ;
TRIJBELS, FJM ;
ESKES, TKAB ;
VANDENHEUVEL, LP ;
MARIMAN, ECM ;
DENHEYER, M ;
ROZEN, R ;
BLOM, HJ .
LANCET, 1995, 346 (8982) :1070-1071
[52]   Serum homocysteine and dementia: Meta-analysis of eight cohort studies including 8669 participants [J].
Wald, David S. ;
Kasturiratne, Anuradhani ;
Simmonds, Mark .
ALZHEIMERS & DEMENTIA, 2011, 7 (04) :412-417
[53]   Progression of regional neuropathology in Alzheimer disease and normal elderly: Findings from the Nun Study [J].
Wolf, DS ;
Gearing, M ;
Snowdon, DA ;
Mori, H ;
Markesbery, WR ;
Mirra, SS .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1999, 13 (04) :226-231
[54]   Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD [J].
Yasui, K ;
Kowa, H ;
Nakaso, K ;
Takeshima, T ;
Nakashima, K .
NEUROLOGY, 2000, 55 (03) :437-440
[55]   Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients [J].
Yuan, Rey-Yue ;
Sheu, Jau-Jiuan ;
Yu, Jia-Ming ;
Hu, Chaur-Jong ;
Tseng, Ing-Jy ;
Ho, Chun-Sum ;
Yeh, Ching-Ying ;
Hung, Ya-Lin ;
Chiang, Tsuey-Ru .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 287 (1-2) :64-68
[56]   Meta-analysis of the methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to Alzheimer's disease [J].
Zhang, Min-Yue ;
Miao, Ling ;
Li, Yan-Sheng ;
Hu, Guang-Yuan .
NEUROSCIENCE RESEARCH, 2010, 68 (02) :142-150
[57]  
Zhu BT, 2002, HISTOL HISTOPATHOL, V17, P1283, DOI 10.14670/HH-17.1283
[58]   Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics:: Importance in pathophysiology and pathogenesis [J].
Zhu, BT .
CURRENT DRUG METABOLISM, 2002, 3 (03) :321-349
[59]   Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions [J].
Zoccolella, S ;
Lamberti, P ;
Iliceto, G ;
Diroma, C ;
Armenise, E ;
Defazio, G ;
Lamberti, SV ;
Fraddosio, A ;
de Mari, M ;
Livrea, P .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2005, 43 (10) :1107-1110
[60]   Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinson's Disease: Potential Implications in Cognitive Dysfunction and Dementia? [J].
Zoccolella, S. ;
Lamberti, S. V. ;
Iliceto, G. ;
Santamato, A. ;
Lamberti, P. ;
Logroscino, G. .
CURRENT MEDICINAL CHEMISTRY, 2010, 17 (28) :3253-3261